Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618422 | 0.85 | MAPT (0.49) | OR51E2 | |
| SCHEMBL15173239 | 0.84 | OR51E2 (0.39) | OR51E2 | |
| SCHEMBL908373 | 0.82 | LMNA (0.35) | OR51E2 | |
| SCHEMBL115219 | 0.82 | TSHR (0.45) | OR51E2 | |
| SCHEMBL93977 | 0.82 | OR51E2 (0.50) | OR51E2 | |
| SCHEMBL4985589 | 0.79 | OR51E2 (0.48) | OR51E2 | |
| SCHEMBL6249794 | 0.79 | OR51E2 (0.48) | OR51E2 | |
| Water SCHEMBL22418485 | 0.79 | OR51E2 (0.55) | OR51E2 | |
| SCHEMBL5081389 | 0.77 | SMN1; SMN2 (0.46) | HCAR2ATM | |
| Ethylene Glycol SCHEMBL3837465 | 0.77 | OR51E2 (0.46) | OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119235804-A | Carbamazepine pharmaceutical composition and preparation method and application thereof | 上海则正医药科技股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118055759-A | Miniature tablet containing losartan for pediatric use | 米达斯制药有限责任公司 | 2024-05-17 | — | — | CN | claimed |
| WO-2023031755-A1 | FORMULATIONS, COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEURODEGENERATIVE DRUGS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-03-09 | — | — | WO | claimed |
| WO-2023002338-A1 | COMPOSITIONS, METHODS OF MAKING AND USING SAME FOR THE DELIVERY OF ULCEROGENIC DRUGS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-01-26 | — | — | WO | claimed |
| EP-0516141-B1 | Pharmaceutical controlled-release composition with bioadhesive properties | RECORDATI CHEM PHARM (CH) | 1996-08-14 | — | — | EP | claimed |
| US-20250375459-A1 | METHODS FOR AMELIORATING COGNITIVE IMPAIRMENT USING BILE ACID DERIVATIVES | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | disclosed |
| CN-120021412-A | Pharmaceutical composition containing heteroaryloxy naphthalene compounds, and preparation method and application thereof | 上海润石医药科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| EP-4547256-A1 | METHODS FOR AMELIORATING COGNITIVE IMPAIRMENT USING BILE ACID DERIVATIVES | Intercept Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119235804-A | Carbamazepine pharmaceutical composition and preparation method and application thereof | 上海则正医药科技股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118055759-A | Miniature tablet containing losartan for pediatric use | 米达斯制药有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024006537-A1 | METHODS FOR AMELIORATING COGNITIVE IMPAIRMENT USING BILE ACID DERIVATIVES | INTERCEPT PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-116669749-A | Use of cannabidiol for treating psychological disorders | 埃米利亚公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023002338-A1 | COMPOSITIONS, METHODS OF MAKING AND USING SAME FOR THE DELIVERY OF ULCEROGENIC DRUGS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-01-26 | — | — | WO | disclosed |
| CN-113874023-A | Methods of using obeticholic acid for diagnosis and treatment of liver disease | 英特塞普特医药品公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113271951-A | Methods of using obeticholic acid | 英特塞普特医药品公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-113226316-A | Crystalline forms and processes of lenvatinib besylate | 斯索恩有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-5571533-A | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1996-11-05 | — | — | US | disclosed |
| EP-0516141-B1 | Pharmaceutical controlled-release composition with bioadhesive properties | RECORDATI CHEM PHARM (CH) | 1996-08-14 | — | — | EP | disclosed |
| US-5472704-A | Particles of active core material coated with controlled release polymer film and mucoadhesive polymer outer layer | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-12-05 | — | — | US | disclosed |
| EP-0516141-A1 | Pharmaceutical controlled-release composition with bioadhesive properties | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375459-A1 | METHODS FOR AMELIORATING COGNITIVE IMPAIRMENT USING BILE ACID DERIVATIVES | SLC10A1, NR1H4, CHAT | OR51E2 4527/4885HCAR2 320/4885ATM 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.